Eledon's Tegoprubart Achieves 100% Insulin Independence in Type 1 Diabetes Trial
Event summary
- All 12 patients in Eledon's investigator-initiated trial achieved insulin independence after islet transplantation with tegoprubart.
- Mean HbA1c improved by 2.6% to approximately 5.4%, with no severe hypoglycemic episodes reported post-transplant.
- Tegoprubart-based immunosuppression showed higher islet cell engraftment and no rejection episodes compared to historical tacrolimus-based regimens.
- Study funded by Breakthrough T1D, with plans for a second trial in patients with chronic kidney disease.
The big picture
Eledon's positive trial results for tegoprubart mark a potential breakthrough in Type 1 Diabetes treatment, offering a calcineurin inhibitor-free immunosuppression regimen that could transform islet cell transplantation outcomes. The data supports broader therapeutic potential for CD40L blockade in transplant rejection, positioning Eledon at the forefront of next-generation immunosuppression therapies. The upcoming FDA guidance and additional trials will be critical in validating tegoprubart's commercial viability.
What we're watching
- Regulatory Pathway
- Whether Eledon can secure FDA guidance for tegoprubart in islet cell transplantation by year-end.
- Clinical Validation
- The pace at which additional trials confirm tegoprubart's efficacy in broader Type 1 Diabetes populations.
- Market Differentiation
- How tegoprubart's calcineurin inhibitor-free regimen positions Eledon against existing immunosuppression therapies.
Related topics